LINC02535/miR-30a-5p/GALNT3 axis contributes to lung adenocarcinoma progression via the NF- κ B signaling pathway

Li, Yue; Zhao, Jian; Zhang, Weijie; Wang, Anqi; Jiao, Min; Cai, Xin; Zhu, Jianjie; Liu, Zeyi; Huang, Jianan

doi:10.1080/15384101.2022.2101336

Cited by 7 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, LINC02535 expression was upregulated in LUAD cells, and knockdown of LINC02535 inhibited the proliferation and migration of LUAD cells in our study, suggesting that LINC02535 could be considered as a risk factor of LUAD, which was in accordance with Li et al's study [ 15 ]. Flow cytometry results found that downregulation of LINC02535 attenuated the G1/S phase transition of the cell cycling, and accelerated apoptosis.…”

Section: Discussionsupporting

confidence: 92%

“…Flow cytometry results found that downregulation of LINC02535 attenuated the G1/S phase transition of the cell cycling, and accelerated apoptosis. Compared to Li et al's study [ 15 ], we proposed for the first time that LINC02535 can inhibit apoptotic cell signaling and activate cell cycle signaling to promote cell growth, which further enhances the understanding that LINC2535 promotes LUAD development. Previous studies have shown that cell cycle dysregulation affects abnormal cell division, thus promoting aberrant cell growth [ 32 ].…”

Section: Discussionmentioning

confidence: 72%

“…In addition, it also plays a synergistic role with PCBP2 promoting DNA damage repair and maintaining the expression of RRM1 mRNA, thus promoting the proliferation of cervical cancer cells and the development of epithelial-mesenchymal transition (EMT) [ 14 ]. In lung cancer, LINC02535 is found to regulate NF-κB signaling pathway via miR-30a-5p/GALNT3 axis, promoting tumor growth [ 15 ]. However, to date, there are still few studies on the role of LINC02535 in diagnosis and treatment of various malignancies.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pan-cancer analysis of LINC02535 as a potential biomarker and its oncogenic role in lung adenocarcinoma

Dai

Liu²,

He³

et al. 2022

Heliyon

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 72%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pan-cancer analysis of LINC02535 as a potential biomarker and its oncogenic role in lung adenocarcinoma

Dai

Liu²,

He³

et al. 2022

Heliyon

View full text Add to dashboard Cite

“…Furthermore, the study revealed that lncRNA DLEU2 may serve as a ceRNA sponge for miR-30e-5p, thus influencing E2F7 expression and promoting ESCA progression. Additionally, previous research has revealed that hsa-miR-30a-5p exhibits significantly lower expression levels in lung adenocarcinoma, renal carcinoma, prostate cancer, and hepatocellular carcinoma compared to normal tissues, highlighting its crucial role as a key component of the ceRNA network in cancer development [ 61 – 64 ]. However, to date, no studies have reported on the relationship between DARS2 and ceRNAs in ESCA.…”

Section: Discussionmentioning

confidence: 99%

Functional enrichment analysis reveals the involvement of DARS2 in multiple biological pathways and its potential as a therapeutic target in esophageal carcinoma

Liu,

Zeng

et al. 2024

Aging

View full text Add to dashboard Cite

Objective: The enzyme Aspartyl tRNA synthetase 2 (DARS2) is a crucial enzyme in the mitochondrial tRNA synthesis pathway, playing a critical role in maintaining normal mitochondrial function and protein synthesis. However, the role of DARS2 in ESCA is unclear. Materials and methods: Transcriptional data of pan-cancer and ESCA were downloaded from UCSC XENA, TCGA, and GEO databases to analyze the differential expression of DARS2 between tumor samples and normal samples, and its correlation with clinicopathological features of ESCA patients. R was used for GO, KEGG, and GSEA functional enrichment analysis of DARS2 co-expression and to analyze the connection of DARS2 with glycolysis and m6A-related genes. In vitro experiments were performed to assess the effects of interfering with DARS2 expression on ESCA cells. TarBase v.8, mirDIP, miRTarBase, ENCORI, and miRNet databases were used to analyze and construct a ceRNA network containing DARS2. Results: DARS2 was overexpressed in various types of tumors. In vitro experiments confirmed that interfering with DARS2 expression significantly affected the proliferation, migration, apoptosis, cell cycle, and glycolysis of ESCA cells. DARS2 may be involved in multiple biological pathways related to tumor development. Furthermore, correlation and differential analysis revealed that DARS2 may regulate ESCA m6A modification through its interaction with METTL3 and YTHDF1. A ceRNA network containing DARS2, DLEU2/has-miR-30a-5p/DARS2, was successfully predicted and constructed. Conclusions: Our findings reveal the upregulation of DARS2 in ESCA and its association with clinical features, glycolysis pathway, m6A modification, and ceRNA network. These discoveries provide valuable insights into the molecular mechanisms underlying ESCA.

show abstract

“…Protein biomarkers, which serve as biochemical indicators reflecting structural or functional changes in various biological levels, have been extensively researched for their diagnostic, prognostic, and therapeutic efficacy prediction capabilities in tumors. Despite limited studies on differential proteins in LUAD progression, this study utilized Olink proteomics to identify IL8 and CCL20 as potential differentiators between tumor and normal tissues, while IL6 and VEGFA emerged as Previous studies have demonstrated correlations between NF-kappa B signaling pathway, 8 Chemokine signaling pathway, 9 IL-17 signaling pathway, 10 and TLR signaling pathway 11 with cancer development. Among these pathways, Interleukin-8 (IL8) is a common participant protein.…”

Section: ■ Discussionmentioning

confidence: 99%

Olink Proteomics-Based Exploration of Immuno-Oncology-Related Biomarkers Leading to Lung Adenocarcinoma Progression

Yu,

Yang,

Shu

et al. 2024

J. Proteome Res.

View full text Add to dashboard Cite

Introduction: It is crucial to investigate the distinct proteins that contribute to the advancement of lung cancer. Material and Methods: We analyzed the expression levels of 92 immunooncology-related proteins in 96 pairs of lung adenocarcinoma tissue samples using Olink proteomics. The differentially expressed proteins (DEPs) were successively screened in tumor and paraneoplastic groups, early and intermediate-late groups by a nonparametric rank sum test, and the distribution and expression levels of DEPs were determined by volcano and heat maps, etc., and the area under the curve was calculated. Results: A total of 24 DEPs were identified in comparisons between tumor and paracancerous tissues. Among them, interleukin-8 (IL8) and chemokine (C−C motif) ligand 20 (CCL20) as potential markers for distinguishing tumor tissues. Through further screening, it was found that interleukin-6 (IL6) and vascular endothelial growth factor A (VEGFA) may be able to lead to tumor progression through the JaK-STAT signaling pathway, Toll-like receptor signaling pathway and PI3K/ AKT signaling pathway. Interestingly, our study revealed a down-regulation of IL6 and VEGFA in tumor tissues compared to paracancerous tissues. Conclusions: IL8 + CCL20 (AUC: 0.7056) have the potential to differentiate tumor tissue from paracancerous tissue; IL6 + VEGFA (AUC: 0.7531) are important protein markers potentially responsible for tumor progression.

show abstract

LINC02535/miR-30a-5p/GALNT3 axis contributes to lung adenocarcinoma progression via the NF- κ B signaling pathway

Cited by 7 publications

References 37 publications

Pan-cancer analysis of LINC02535 as a potential biomarker and its oncogenic role in lung adenocarcinoma

Pan-cancer analysis of LINC02535 as a potential biomarker and its oncogenic role in lung adenocarcinoma

Functional enrichment analysis reveals the involvement of DARS2 in multiple biological pathways and its potential as a therapeutic target in esophageal carcinoma

Olink Proteomics-Based Exploration of Immuno-Oncology-Related Biomarkers Leading to Lung Adenocarcinoma Progression

Contact Info

Product

Resources

About